| Opinion | By Dr Manbeena Chawla
With cell and gene therapy (CGT) representing a major advancement in medical treatments by directly targeting the root causes of diseases at the cellular or genetic level, GlobalData’s latest report predicts the CGT market to be worth $76 billion by 2030. Reports also reveal that the North America region captured the highest revenue share of the CGT market in 2024. To find out more about the new developments taking place in the CGT sector, particularly in the US, BioSpectrum Asia spoke with Amy C Hay, Chief Business Officer, Cell Therapy Manufacturing Center (CTMC), a joint venture between University of Texas MD Anderson Cancer Center and National Resilience, Inc. in the United States.
Access the article: BioSpectrum Asia